Research programme: anti-VEGF therapeutics - Pharmexa

Drug Profile

Research programme: anti-VEGF therapeutics - Pharmexa

Alternative Names: VEGF AutoVac

Latest Information Update: 05 Sep 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmexa
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Sep 2007 Discontinued - Preclinical for Cancer in Denmark (Parenteral)
  • 11 Jan 2005 Pharmexa and Epimmune have expanded their non-exclusive licence agreement of 2001 to include additional target antigens
  • 09 Jul 2004 Preclinical trials in Cancer in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top